A Physiological Study to Evaluate Liver Function in Male and Female Patients Infected with COVID-19 Virus in Najaf City

Hanan Diekan  Abbas; Sajjad Jubair Kadhim

doi:10.3889/oamjms.2022.9427

Authors

Hanan Diekan Abbas Department of Physiology, Faculty of Medicine, Jabir ibn Hayyan Medical University, Najaf City, Iraq
Sajjad Jubair Kadhim Department of Community Health, Faculty of Health and Medical Techniques, Al-Furat Al-Awsat Technical University, Najaf City, Iraq

DOI:

https://doi.org/10.3889/oamjms.2022.9427

Keywords:

COVID-19, Liver enzymes, Liver injury, TBiL

Abstract

COVID-19 infection usually causes respiratory distress syndrome. Liver impairment has been reported, there is no clear mechanism for liver damage. Liver damage may be due to other factors, such as a viral infection or inflammations in the liver. Lack of information among the residents of the city of Najaf about the differences between males and females infected with the “Corona Virus” disease (“Covid-19”). In this study, we focus on the effects of (“COVID-19”) on liver physiology in 60 (“COVID-19”) patients (20-70 years old). Examinations, taking into account demographic information as well as clinical findings, show that the patient has liver abnormalities. The result indicated increasing of liver enzymes ALT,AST,ALP and TBiL levels on patients with covid-19 Corona Virus.Males patients had a higher risk of liver enzymes level elevation than females. ("TBiL") concentrations were highly increased when compared with control. In critical patients, severe liver cells abnormalities result from ("COVID-19"), which requires follow-up and immediate therapeutic intervention. Because of its strong relationship with the severity of the injury in ("COVID-19"), ALT,AST,ALP, and TBiL it is expected to be of great importance in the future prediction and diagnosis of infection.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Wang L, He WB, Yu XM, Hu DL, Jiang H. Prolonged prothrombin time at admission predicts poor clinical outcome in COVID- 19 patients. World J Clin Cases. 2020;8(19):4370-9. https://doi.org/10.12998/wjcc.v8.i19.4370 PMid:33083396 DOI: https://doi.org/10.12998/wjcc.v8.i19.4370

Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417-8. https://doi.org/10.1016/S0140-6736(20)30937-5 PMid:32325026 DOI: https://doi.org/10.1016/S0140-6736(20)30937-5

Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. N Engl J Med. 2020;383(2):120-8. https://doi.org/10.1056/NEJMoa2015 432 PMid:32437596 DOI: https://doi.org/10.1056/NEJMoa2015432

Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094-9. https://doi.org/10.1111/jth.14817 PMid:32220112 DOI: https://doi.org/10.1111/jth.14817

Iba T, Levy JH, Warkentin TE, Thachil J, van der Poll T, Levi M. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost. 2019;17(11):1989-94. https://doi.org/10.1111/jth.14578 PMid:31410983 DOI: https://doi.org/10.1111/jth.14578

Gurala D, Al Moussawi H, Philipose J, Abergel JR. Acute liver failure in a COVID-19 patient without any preexisting liver disease. Cureus. 2020;12(8):e10045. https://doi.org/10.7759/cureus.10045 PMid:32983735 DOI: https://doi.org/10.7759/cureus.10045

Melquist S, Estepp K, Aleksandrovich Y, Lee A, Beiseker A, Hamedani FS, et al. COVID-19 presenting as fulminant hepatic failure: A case report. Medicine (Baltimore). 2020;99(43):e22818. https://doi.org/10.1097/MD.0000000000022818 PMid:33120805 DOI: https://doi.org/10.1097/MD.0000000000022818

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9. https://doi.org/10.1001/jama.2020.1585 PMid:32031570 DOI: https://doi.org/10.1001/jama.2020.1585

Shalimar, Elhence A, Vaishnav M, Kumar R, Pathak P, Soni KD, et al. Poor outcomes in patients with cirrhosis and Corona Virus Disease-19. Indian J Gastroenterol. 2020;39(3):285-91. https://doi.org/10.1007/s12664-020-01074-3 PMid:32803716 DOI: https://doi.org/10.1007/s12664-020-01074-3

Gerussi A, Rigamonti C, Elia C, Cazzagon N, Floreani A, Pozzi R, et al. Coronavirus disease 2019 (COVID-19) in autoimmune hepatitis: A lesson from immunosuppressed patients. Hepatol Commun. 2020;4(9):1257-62. https://doi.org/10.1002/hep4 PMid:32838102 DOI: https://doi.org/10.1002/hep4.1557

Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631-7. https://doi.org/10.1002/path.1570 PMid:15141377 DOI: https://doi.org/10.1002/path.1570

Lenti MV, de Andreis FB, Pellegrino I, Klersy C, Merli S, Miceli E, et al. Impact of COVID 19 on liver function: results from an internal medicine unit in Northern Italy. Intern Emerg Med. 2020;15(8):1399-407. https://doi.org/10.1007/s11739-020-02425-w PMid:32651938 DOI: https://doi.org/10.1007/s11739-020-02425-w

Zarifian A, Zamiri Bidary M, Arekhi S, Rafiee M, Gholamalizadeh H, Amiriani A, et al. Gastrointestinal and hepatic abnormalities in patients with confirmed COVID- 19: A systematic review and meta-analysis. J Med Virol. 2021;93(1):336-50. https://doi.org/10.1002/jmv.26314 PMid:32681674 DOI: https://doi.org/10.1002/jmv.26314

Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv. 2020;181:271-80. https://doi.org/10.1101/2020.01.31.929042 DOI: https://doi.org/10.1101/2020.01.31.929042

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-80.e8. https://doi.org/10.1016/j.cell.2020.02.052 PMid:32142651 DOI: https://doi.org/10.1016/j.cell.2020.02.052

Aizarani N, Saviano A, Sagar, Mailly L, Durand S, Herman JS, et al. A human liver cell atlas reveals heterogeneity and epithelial progenitors. Nature. 2019;572(7768):199-204. https://doi.org/10.1038/s41586-019-1373-2 PMid:31292543 DOI: https://doi.org/10.1038/s41586-019-1373-2

Awadasseid A, Wu Y, Tanaka Y, Zhang W. Initial success in the identification and management of the coronavirus disease 2019 (COVID-19) indicates human-to-human transmission in Wuhan, China. Int J Biol Sci. 2020;16(11):1846-60. https://doi.org/10.7150/ijbs.45018 PMid:32398954 DOI: https://doi.org/10.7150/ijbs.45018

Fan H, Cai J, Tian A, Li Y, Yuan H, Jiang Z, et al. Comparison of liver biomarkers in 288 COVID-19 patients: A mono-centric study in the early phase of pandemic. Front Med (Lausanne). 2021;7:584888. https://doi.org/10.3389/fmed.2020.584888 PMid:33521010 DOI: https://doi.org/10.3389/fmed.2020.584888

Moura DT, Proença IM, McCarty TR, Sagae VM, Ribeiro IB, Oliveira GH, et al. Gastrointestinal manifestations and associated health outcomes of COVID-19: A Brazilian experience from the largest South American public hospital. Clinics (Sao Paulo). 2020;75:e2271. https://doi.org/10.6061/clinics/2020/e2271 PMid:33146362 DOI: https://doi.org/10.6061/clinics/2020/e2271

Kulkarni AV, Kumar P, Tevethia HV, Premkumar M, Arab JP, Candia R, et al. Systematic review with meta-analysis: Liver manifestations and outcomes in COVID-19. Aliment Pharmacol Ther. 2020;52(4):584-99. https://doi.org/10.1111/apt.15916 PMid:32638436 DOI: https://doi.org/10.1111/apt.15916

Elhence A, Vaishnav M, Biswas S, Chauhan A, Anand A, Shalimar. Coronavirus disease-2019 (COVID-19) and the liver. J Clin Transl Hepatol 2021;9:247-55. https://doi.org/10.14218/JCTH.2021.00006 PMid:34007807 DOI: https://doi.org/10.14218/JCTH.2021.00006

Wen Seow JJ, Pai R, Mishra A, Shepherdson E, Hon Lim TK, Goh BK, et al. scRNA-seq reveals ACE2 and TMPRSS2 expression in TROP2+ liver progenitor cells: implications in COVID-19 associated liver dysfunction. bioRxiv. 2020. https://doi.org/10.1101/2020.03.23.002832 DOI: https://doi.org/10.1101/2020.03.23.002832

Zhang XJ, Cheng X, Yan ZZ, Fang J, Wang X, Wang W, et al. An ALOX12-12-HETE-GPR31 signaling axis is a key mediator of hepatic ischemia-reperfusion injury. Nat Med. 2018;24(1):73-83. https://doi.org/10.1038/nm.4451 PMid:29227475 DOI: https://doi.org/10.1038/nm.4451

Lumeij JT, De Bruijne JJ, Slob A, Wolfswinkel J, Rothuizen J. Enzyme activities in tissues and elimination half-lives of homologous muscle and liver enzymes in the racing pigeon (Columba Livia domestica). Avian Pathol. 2008;17(4):851-64. https://doi.org/10.1080/03079458808436507 PMid:18766746 DOI: https://doi.org/10.1080/03079458808436507

World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. Available https://covid19.who.int/. [Last accessed on 2021 May 25].

Mao R, Qiu Y, He JS, Tan JY, Li XH, Liang J, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(7):667-78. https://doi.org/10.1016/S2468-1253(20)30126-6 PMid:32405603 DOI: https://doi.org/10.1016/S2468-1253(20)30126-6